Thrombembolic complications after total ankle replacement

Alexej Barg · Katharina Barg · Stefan W. Schneider ·
Geert Pagenstert · Marcel Gloyer · Heath B. Henninger ·
Victor Valderrabano

Published online: 28 September 2013
© Springer Science+Business Media New York 2013

Abstract The literature addressing functional outcome and survivorship of prosthesis components is constantly growing. However, the data on thromboprophylaxis and thrombembolic complications in patients who underwent TAR are scarce. A total of 31 studies were included in the systemic literature review. The incidence of thrombembolic complications varied between 0.0 % and 9.8 %. Most commonly, low molecular weight heparin was used as thromboprophylaxis for 6 weeks postoperatively. The incidence of thrombembolic complications was comparable with that of symptomatic deep vein thrombosis in patients with total knee or hip replacement.

Keywords Total ankle replacement · Thromboprophylaxis · Thrombembolic complications · Thrombosis · Deep vein thrombosis · Pulmonary embolism

Alexej Barg and Katharina Barg contributed equally to this review work. This review was performed by Katharina Barg in the fulfillment of the thesis requirements for the Medical Degree (MD).

A. Barg (✉) · G. Pagenstert · M. Gloyer
Orthopaedic Department, University Hospital of Basel, University of
Basel, Spitalstrasse 21, 4031 Basel, Switzerland
e-mail: alexej.barg@usb.ch

V. Valderrabano
Department of Orthopaedic Surgery and Osteoarthritis Research
Center Basel, University Hospital of Basel, 4031 Basel, Switzerland

K. Barg
Department of Internal Medicine, Clinic Ibbenbüren,
49477 Ibbenbüren, Germany

S. W. Schneider
Department of Dermatology, Venerology, and Allergology,
University Medical Center and Medical Faculty Mannheim,
University of Heidelberg, 68167 Mannheim, Germany

H. B. Henninger
Department of Orthopaedics, Harold K. Dunn Orthopaedic Research
Laboratory, University of Utah, Salt Lake City, UT 84108, USA

Introduction

Total ankle replacement (TAR) is gaining acceptance as a viable treatment option in patients with end-stage ankle osteoarthritis [1, 2, 3]. In 2009, Saltzman et al. [4] published findings from a prospective controlled trial of the Scandinavian Total Ankle Replacement System (STAR) vs ankle fusion and reported TAR led to better functional outcome and similar postoperative pain relief compared with ankles that were fused. Several prosthesis designs are available on the market. While the STAR prosthesis is the only 3-component total ankle design with FDA approval in the United States [4–6], the most common ankle prostheses in Europe are 3-component designs [5, 7–9]. A recent review by Valderrabano et al. [10] revealed no obvious differences in clinical outcomes between prosthesis types, yet biomechanical and kinematic studies show advantages of 3-component designs [11–14].

A review by Glazebrook et al. [15] provided a summary of TAR implant survival and complications in second or third generation ankle prostheses, and established a complication classification system. In total, 9 main complications were identified but thromboembolic complications were not among them. Thromboembolic complications are often mentioned as a possibility postoperatively [16–21], however, the exact incidence of postoperative thromboembolism is unknown. Furthermore, the use of thromboprophylaxis in patients who undergo TAR remains controversial [20, 22–25]. Conti and Wong [26] stated that thromboembolic prophylaxis should be at the surgeon's discretion. The same authors concluded that deep vein thrombosis is an uncommon complication after TAR, where careful surgical technique and standard deep vein thrombosis prophylaxis can help minimize the risk [16]. Gadgil et al. [27] performed an email-based survey of American and British foot and ankle surgeons. Only 19 % of surgeons routinely used thromboprophylaxis in both elective and trauma foot and ankle surgery. The most common indication

for use of thromboprophylaxis was postoperative immobilization and non-weight-bearing rehabilitation [27].

We performed a systematic literature review of relevant clinical studies targeting the following criteria: postoperative thromboembolic complications including deep vein thrombosis and/or pulmonary embolism, and the method and duration of thrombosis prophylaxis.

Systematic literature search

We reviewed the literature using PubMed, MEDLINE, Embase, CINAHL, Cochrane Central Register of Controlled Trials (CENTRAL), ScienceDirect, and SpringerLink. All searches were unlimited, including publications in all languages and at all dates. All types of publications including prospective and retrospective studies, case reports, and review articles that explored the clinical outcome after primary and revision TAR were included. We also searched the electronic contents of several orthopedic and specifically foot and ankle journals including Foot and Ankle International, Journal of Bone and Joint Surgery (American Volume), Journal of Bone and Joint Surgery (British Volume, currently known as The Bone and Joint Journal), Clinical Orthopaedics and Related Research, Foot Ankle Clinics of North America, Journal of Foot and Ankle Surgery, and Orthopäde. We supplemented our search strategy by a manual search of the bibliographies of all identified studies. All online searches were done in duplicate.

We searched the databases for the following keywords: “total ankle replacement”, “total ankle arthroplasty”, “ankle replacement”, “ankle arthroplasty”, “ankle prosthesis”. Secondary keywords used in the search strategy were: “thrombosis”, “deep vein thrombosis”, “pulmonary embolism”, “thromboprophylaxis.” The last search was performed on July 1, 2013.

Identification of relevant studies

Study eligibility was assessed independently and in duplicate, and the assessments were then crosschecked. The following data were identified as relevant and extracted for further review: method of thromboprophylaxis, duration of thromboprophylaxis, and documented postoperative thromboembolic complications.

All included studies have been described using following criteria: type of study (multi-center, single-center, case report), type of data collection (prospective, retrospective, retrospective review of prospectively collected data), level of evidence (assessment using the Journal of Bone and Joint Surgery ranking system) [28], patient cohort (number of patients who underwent TAR, number of replaced ankles), and ankle prosthesis type.

Included studies

In total, 30 clinical studies have been examined based on the inclusion criteria (Table 1). All studies were published between 1999 and 2013 with 13 (43.3 %) prospective (2 of them retrospective reviews of prospectively collected data) and 17 (56.7 %) retrospective studies. Two of the 30 studies (6.7 %) were case reports with 1 patient each. Only 1 study was multicenter in design. For the included articles, the levels of evidence ranged from II to V. There were 4 (13.3 %) level II studies, 24 (80.0 %) level IV studies, and 2 (6.7 %) level V studies (2 case reports).

Total ankle replacement

Disregarding the 2 case reports the number of total ankle arthroplasties varied between 10 and 722 (median 58 ankle arthroplasties) (Table 1). Eight different prosthesis designs were used: Scandinavian Total Ankle Replacement (STAR) [60] (10 studies, 32.3 %), HINTEGRA [34] (11 studies, 35.5 %), Ankle Evolutive System (AES) [61] (2 studies, 6.5 %), Agility [62] (2 studies, 6.5 %), Buechel-Pappas [63] (1 study, 3.2 %), INBONE [64] (1 study, 3.2 %), and Mobility [65] (1 study, 3.2 %). In 2 studies different prosthesis types (STAR/Buechel-Pappas prosthesis and STAR/Salto/INBONE prosthesis) were used. In 1 study custom made prosthesis components (based on the STAR) were used in a patient with traumatic loss of the talus. In most studies (26 studies, 83.9 %) a 3-component prosthesis design was used. In 23 studies (74.2 %) an intraoperative use of tourniquet was documented (Table 2). In 24 studies (77.4 %) postoperative rehabilitation was described in detail (Table 2). Most commonly full weight-bearing was allowed after surgery (12 studies, 38.7 %). In 5 studies (16.1 %) non-weight-bearing was chosen for postoperative rehabilitation. In 7 studies (22.6 %) both rehabilitation styles were used (first non-weight-bearing, then full or partial weight-bearing) in the first 6 week postoperative course. In total, 3 different types of immobilization were used: stable walker, cast, or posterior splint.

Thromboprophylaxis

In 23 of 31 studies (74.2 %) the method of thromboprophylaxis was described. In all but 2 studies low-molecular-weight heparin (LMWH) was used. In 1 study (case report with bilateral knee and ankle replacement) LMWH was used for the first 2 weeks, then oral medication with phenprocoumon was continued for 5 months. In another study oral medication with aspirin twice daily was used. In 18 of 31 studies (58.1 %) the duration of thromboprophylaxis was indicated, most commonly for 6 weeks (15 studies, 51.6 %).

Table 1 Included clinical studies reporting the postoperative incidence of deep-vein thrombosis and/or type of thromboprophylaxis in patients after total ankle replacement

Study	Type of study	LoE	Patients (ankles)	Prosthesis type	Thromboprophylaxis	DVT (n, %)	Localization of DVT
Bardelli & Scoccianti, 2006 [29]	RS, SC	IV	24 (24)	STAR (24)	LMWH, duration not known	0 (0.0 %)	-
Barg et al. 2010 [30]	PS, SC	II	69 (92)	HINTEGRA (92)	LMWH for 6 wk	0 (0.0 %)	-
Barg et al. 2011 [31]	PS, SC	IV	26* (52)	HINTEGRA (52)	LMWH for 6 wk	0 (0.0 %)	-
Barg et al. 2011 [32•]	PS, SC	II	665 (701)	HINTEGRA (701)	LMWH for 6 wk	26 (3.7 %)	peroneal (18), posterior tibial (2), peroneal & posterior tibial (2), popliteal (2), superficial femoral (1), posterior tibial and superficial femoral (1)
Barg et al. 2011 [33]	RS, SC	IV	118 (123)	HINTEGRA (123)	LMWH for 6 wk	12 (9.8 %)	peroneal (12)
Barg et al. 2012 [34]	PS, SC	IV	301 (311)	HINTEGRA (311)	LMWH for 6 wk	n.a.	-
Barg et al. 2013 [35]	PS, SC	IV	684 (722)	HINTEGRA (722)	LMWH for 6 wk	n.a.	-
Besse et al. 2009 [36]	PS, SC	IV	47 (50)	AES (50)	n.a.	1 (2.0 %)	popliteal (1)
Bleuzey et al. 2013 [37]	RS, SC	IV	57 (58)	INBONE (58)	n.a.	2 (3.4 %)	n.a.
Clement et al. 2013 [38]	RS, SC	IV	26 (26)	STAR (14), Salto (11), INBONE (1)	Aspirin (325 mg) twice daily for 6 wk	0 (0.0 %)	-
Dhawan et al. 2012 [39]	RS, SC	IV	29 (30)	Buechel-Pappas (30)	LMWH for 6 wk	n.a.	-
Gallardo et al. 2012 [40]	PS, SC	II	30 (30)	HINTEGRA (30)	LMWH, duration not known	n.a.	-
Haskell & Mann, 2004 [41]	RS, MC	IV	187 (187)	STAR (187)	n.a.	2 (1.1 %)	n.a.
Hintermann, 1999 [42]	PS, SC	IV	47 (50)	STAR (50)	LMWH for 6 wk	0 (0.0 %)	n.a.
Hintermann & Valderabano, 2001 [43]	RS, SC	IV	76 (79)	STAR (79)	LMWH for 6 wk	n.a.	-
Hintermann et al. 2006 [44]	PS, SC	IV	261 (271)	HINTEGRA (271)	LMWH for 6 wk	n.a.	-
Hobson et al. 2009 [45]	RS, SC	II	111 (123)	STAR (123)	n.a.	0 (0.0 %)	-
Karantana et al. 2010 [46]	RS, SC	IV	45 (52)	STAR (52)	n.a.	0 (0.0 %)	-
Karantana et al. 2010 [47]	RS, SC	IV	5* (10)	STAR (10)	LMWH, duration not known	0 (0.0 %)	-
Knecht et al. 2004 [48]	RS, SC	IV	126 (132)	Agility (132)	n.a.	1 (0.8 %)	localization not known, DVT with documented pulmonary embolism without any long-term sequelae
Kokkonen et al. 2011 [49]	RS, SC	IV	37 (38)	AES (38)	LMWH, duration not known	n.a.	-
Kumar & Dhar, 2007 [50]	RS, SC	IV	43 (50)	STAR (50)	LMWH, duration not known	0 (0.0 %)	-
Lee et al. 2008 [51]	RS, SC	IV	50 (50)	HINTEGRA (50)	n.a.	0 (0.0 %)	-
Magnan et al. 2004 [52]	CR	V	1 (1)	Custom made	LMWH for 4 wk	0 (0.0 %)	-
Pagenstert & Hintermann, 2011 [53]	CR	V	2† (1)	HINTEGRA (2)	LMWH for 2 wk, Phenprocoumon for 5 m	0 (0.0 %)	-
Rippstein et al. 2011 [54]	PS, SC	IV	233 (240)	Mobility (240)	LMWH for 6 wk	3 (1.3 %)	n.a.
Rzesacz & Gossé, 2007 [55]	RS, SC	IV	13 (13)	STAR (13)	LMWH for 6 wk	0 (0.0 %)	-
Saltzman et al. 2010 [56]	RS, SC	IV	42 (42)	STAR (42)	n.a.	2 (4.8 %)	-

Table 1 (continued)

Study	Type of study	LoE	Patients (ankles)	Prosthesis type	Thromboprophylaxis	DVT (n, %)	Localization of DVT
Valderrabano & Hintermann, 2004 [57]	PS, SC	IV	119 (125)	HINTEGRA (125)	LMWH for 6 wk daily	n.a.	-
van der Heide et al. 2009 [58]	RS, SC	IV	54 (58)	Agility (58)	LMWH for 6 wk	n.a.	-
Vienne, 2005 [59]	RS, SC	IV	85 (85)	Agility (85)	LMWH for 6 wk	n.a.	-

*all patients underwent simultaneous bilateral total ankle replacement

† patient underwent simultaneous bilateral total ankle replacement and bilateral total knee replacement

AES Ankle evolute system, CR case report, DVT deep vein thrombosis, LMWH low molecular weight heparin, LoE level of evidence, M months, MC multicenter, n.a. not available, RS retrospective, SC single-center, STAR Scandinavian Total Ankle Replacement, Wk weeks

Incidence of thromboembolic complications

In 12 of 31 studies (35.5 %) the incidence of thromboembolic complications was not specified. In 13 of 31 studies (41.9 %) no thromboembolic complications were observed (Table 1). In 7 of 31 studies (22.6 %) the incidence of thromboembolic complications varied between 0.8 % and 9.8 % (median 2.0 %). In most cases, symptomatic deep vein thrombosis was observed. Only 1 patient presented with deep vein thrombosis and pulmonary embolism. In 3 studies exact localization of deep vein thrombosis was described, most commonly found in distal veins of the lower extremity.

Authors' preferred treatment

In our clinic, all patients receive thromboprophylaxis with subcutaneous LMWH (Fragmin, 5000 IE or weight-adjusted, Pfizer AG, Zürich), starting 12 hours preoperatively and continuing daily for 6 weeks postoperatively. In the last 36 months an alternative oral application of rivaroxaban (Xarelto, 10 mg, Bayer AG, Zürich) has been used. Rivaroxaban has been shown to be superior to enoxaparin for thromboprophylaxis after total knee [66] and total hip replacement [67] with similar rates of bleeding. However, to date there is no literature addressing the efficacy and safety of rivaroxaban in patients who underwent foot and ankle surgery.

After surgery, a splint is used to keep the foot in a neutral position. When the wound is dry and no secretion is present, the foot is placed in a stabilizing walker or cast for 6 to 8 weeks. In patients with additional procedures (eg, fusion of adjacent joint or corrective osteotomies), the immobilization can be prolonged until osseous healing at the site of fusion and/or osteotomy is verified. Weight-bearing is allowed as tolerated with the exception of patients who underwent additional corrective osteotomies. Active and passive mobilization of the first metatarsophalangeal joint may increase venous blood flow of the lower extremity, which results in an anti-edema and thromboprophylactic effect [68].

In patients with suspicion of deep vein thrombosis, color duplex sonography is considered. This method is increasingly used as an alternative, noninvasive method for DVT diagnosis. The high sensitivity and specificity of both duplex compression ultrasonography and color-flow Doppler imaging has been shown previously [69, 70]. However, its efficacy as a screening tool in asymptomatic patients with proximal thrombi remains controversial [71]. Our sonography results are considered reliable since they are performed by experienced vascular radiologists [72]. The data on thromboprophylaxis and thromboembolic complications in patients who underwent TAR are scarce. To date, there is only 1 study specifically addressing the incidence of thromboembolic complications and risk factors for those in patients with TAR [32•].

Table 2 Included clinical studies reporting type postoperative mobilization and use of tourniquet in patients after total ankle replacement

Study	Postoperative Mobilization	Use of Tourniquet	DVT (n,%)
Bardelli & Scoccianti, 2006 [29]	Full weight-bearing in a cast for 6 wk	n.a.	0 (0.0 %)
Barg et al. 2010 [30]	Full weight-bearing in a stable walker for 6 wk	yes	0 (0.0 %)
Barg et al. 2011 [31]	Full weight-bearing in a stable walker for 6 wk	yes	0 (0.0 %)
Barg et al. 2011 [32]	Full weight-bearing in a cast or a stable walker for 6 wk (610 ankles), non-weight-bearing in a cast or a stable walker for 6 wk (91 ankles)	yes	26 (3.7 %)
Barg et al. 2012 [34]	Full or partial weight-bearing in a cast or a stable walker for 6 wk	yes	n.a.
Barg et al. 2013 [35]	Full or partial weight-bearing in a cast or a stable walker for 6 wk	yes	n.a.
Besse et al. 2009 [36]	Cast immobilization for 45 days in 92 % of cases, with a maximum of 75 days	n.a.	1 (2.0 %)
Bleazey et al. 2013 [37]	Non-weight-bearing in a posterior splint for 2 wk, then mobilization in a sneaker	yes	2 (3.4 %)
Dhawan et al. 2012 [39]	Non-weight-bearing in a cast for 6 wk	yes	n.a.
Gallardo et al. 2012 [40]	n.a.	yes	n.a.
Hintermann, 1999 [42]	Full weight-bearing in a cast or a walker for 6 wk	yes	0 (0.0 %)
Hintermann & Valderrabano, 2001 [43]	Full weight-bearing in a cast or a walker for 6 wk	n.a.	n.a.
Hintermann et al. 2006 [44]	Full weight-bearing in a cast or a walker for 6 wk	yes	n.a.
Hobson et al. 2009 [45]	Touch weight-bearing in a cast for 6 wk	n.a.	0 (0.0 %)
Karantana et al. 2010 [46]	Non-weight-bearing in a cast for 6 wk and fully weight-bearing in an Aircast walker for a further 6 wk	n.a.	0 (0.0 %)
Karantana et al. 2010 [47]	Full weight-bearing in a plaster walking cast for 2 wk, then below knee walking cast or Donjoy pneumatic walker for a further 4 wk	yes	0 (0.0 %)
Knecht et al. 2004 [48]	Non-weight-bearing in a posterior splint for 6 wk	yes	1 (0.8 %)
Kokkonen et al. 2011 [49]	Non-weight-bearing in a cast for 2 wk, partial weight-bearing in a cast for a further 2 wk, full weight-bearing in a cast for a further 2 wk	yes	n.a.
Kumar & Dhar, 2007 [50]	Full weight-bearing in a plaster cast for 6 wk	yes	0 (0.0 %)
Magnan et al. 2004 [52]	Non-weight-bearing for 1 week, full-weight-bearing in a below knee brace for a further 5 wk	n.a.	0 (0.0 %)
Pagenstert & Hintermann, 2011 [53]	Full weight-bearing in a cast for 8 wk	yes	0 (0.0 %)
Rippstein et al. 2011 [54]	Full weight-bearing in a removable walker for 6 wk	yes	0 (0.0 %)
Rzesacz & Gossé, 2007 [55]	Full weight-bearing in a walker for 6 wk	yes	3 (1.3 %)
Valderrabano & Hintermann, 2004 [57]	Full weight-bearing in a cast or a walker for 6 wk	yes	0 (0.0 %)
van der Heide et al. 2009 [58]	Non-weight-bearing for 2 wk, full-weight-bearing in a cast for a further 2 wk	yes	n.a.
Vienne, 2005 [59]	Non-weight-bearing in a synthetic cast for 2 wk, 15 kg partial weight-bearing without cast for a further 4 wk	yes	n.a.

DVT deep vein thrombosis, n.a. not available

Conclusions

TAR is gaining increasing acceptance among orthopedic surgeons as a valuable treatment option in patients with end-stage ankle OA. The number of studies in the literature addressing outcomes after TAR is growing; however, many are only reporting functional outcomes or survivorship of prosthesis components.

In a previous study we identified the following statistically significant independent risk factors for symptomatic deep vein thrombosis: obesity, a previous venous thromboembolic event, and the absence of full postoperative weight-bearing [32•]. A previous venous thromboembolic event was the most important risk factor with the odds ratio of 7.07 (95 % confidence interval 2.99 to 16.73). Similar findings were observed in patients who underwent total knee or hip replacement [73, 74]. Another important risk factor for symptomatic deep vein thrombosis of the lower extremity in patients with TAR was obesity ($\text{BMI} \geq 35 \text{ kg/m}^2$) with an odds ratio of 6.94 (95 % confidence interval 2.22 to 21.68). Obese patients who underwent total knee or hip replacement have also higher risk of thromboembolic complications [75–77]. Finally, postoperative non-weight-bearing was associated with an increased incidence of symptomatic deep vein thrombosis resulting in the odds ratio 4.53 (95 % confidence interval 1.86 to 11.00). In another clinical study of patients with Achilles tendon injury, prolonged immobilization in a cast without weight-bearing was also associated with increased incidence of thromboembolic complications [78]. Conversely, early mobilization after total knee replacement resulted in a 30-fold reduction in the risk of deep vein thrombosis [79]. Malignant tumor disease has been shown to be an important risk factor for development of deep vein thrombosis [80, 81]. However, we have not observed co-incidence between this comorbidity and increased incidence of thromboembolic complications. Other factors were not associated with increased incidence of deep vein thrombosis in our study: higher age (≥ 60 years), gender, preoperative American Society of Anesthesiologists classification, tobacco use, surgery duration (≥ 120 min), anesthesia method (spinal vs general), postoperative mobilization (stable walker vs cast), or additional surgical procedures (eg, arthrodesis of adjacent joints) [32•]. Furthermore, it has been shown that patients with bilateral ankle osteoarthritis can be safely treated as simultaneous bilateral procedures with the use of thromboprophylaxis [30, 31, 32•].

In our clinic all patients with TAR receive thromboprophylaxis with subcutaneous LMWH. In the literature the question of whether TAR patients need thromboprophylaxis or not remains unanswered. Jameson et al. [82] analyzed venous thromboembolic events following foot and ankle surgery in the English National Health Service between January 2005 and June 2008. In total, 1633 patients with TAR were included into this study. No deep vein thrombosis and only case of non-fatal

pulmonary embolism (0.061 %) were observed [82]. However, in recent literature the incidence of thromboembolic complications should not be underestimated [23, 27]. Based on our experience we suggest thromboprophylaxis in patients who undergo TAR, especially those with the aforementioned risk factors.

Compliance with Ethics Guidelines

Conflict of Interest Alexej Barg declares that he has no conflict of interest. Katharina Barg declares that she has no conflict of interest. Stefan W. Schneider declares that he has no conflict of interest. Geert Pagenstert declares that he has no conflict of interest. Marcel Gloyer declares that he has no conflict of interest. Heath B. Henninger declares that he has no conflict of interest. Victor Valderrabano declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. • Demetracopoulos CA, Halloran JP, Maloof P, et al. Total ankle arthroplasty in end-stage ankle arthritis. *Curr Rev Musculoskelet Med*. 2013. *Very recent review highlighting indications, advantages, disadvantages, and clinical outcomes of total ankle arthroplasty in patients with end-stage osteoarthritis*.
2. Easley ME, Adams Jr SB, Hembree WC, et al. Current concepts review: results of total ankle arthroplasty. *J Bone Joint Surg Am*. 2011;93:1455–68.
3. • Gougoulas N, Khanna A, Maffulli N. How successful are current ankle replacements?: a systematic review of the literature. *Clin Orthop Relat Res*. 2010;468:199–208. *Recent systematic literature review including 13 Level IV studies with a total of 1105 ankle arthroplasties. The overall failure rate was approximately 10% after 5 years with a wide range between 0% and 32%. This review could not support superiority of any implant design*.
4. Saltzman CL, Mann RA, Ahrens JE, et al. Prospective controlled trial of STAR total ankle replacement vs ankle fusion: initial results. *Foot Ankle Int*. 2009;30:579–96.
5. Guyer AJ, Richardson G. Current concepts review: total ankle arthroplasty. *Foot Ankle Int*. 2008;29:256–64.
6. Mann JA, Mann RA, Horton E. STAR ankle: long-term results. *Foot Ankle Int*. 2011;32:473–84.
7. Besse JL, Colombier JA, Asencio J, et al. Total ankle arthroplasty in France. *Orthop Traumatol Surg Res*. 2010;96:291–303.
8. Goldberg AJ, Sharp RJ, Cooke P. Ankle replacement: current practice of foot & ankle surgeons in the United kingdom. *Foot Ankle Int*. 2009;30:950–4.
9. Gougoulas N, Maffulli N. History of total ankle replacement. *Clin Podiatr Med Surg*. 2013;30:1–20.
10. • Valderrabano V, Pagenstert GI, Muller AM, et al. Mobile- and fixed-bearing total ankle prostheses: is there really a difference? *Foot Ankle*

- Clin. 2012;17:565–85. *Recent review highlighting the currently available total ankle designs. Some advantages of 3-component prosthesis design were observed in biomechanical studies. However, no obvious difference in clinical outcome between 3-component and 2-component prosthesis designs could be identified in the current literature.*
11. Espinosa N, Walti M, Favre P, et al. Misalignment of total ankle components can induce high joint contact pressures. *J Bone Joint Surg Am.* 2010;92:1179–87.
 12. Valderrabano V, Hintermann B, Nigg BM, et al. Kinematic changes after fusion and total replacement of the ankle: part 3: Talar movement. *Foot Ankle Int.* 2003;24:897–900.
 13. Valderrabano V, Hintermann B, Nigg BM, et al. Kinematic changes after fusion and total replacement of the ankle: part 2: movement transfer. *Foot Ankle Int.* 2003;24:888–96.
 14. Valderrabano V, Hintermann B, Nigg BM, et al. Kinematic changes after fusion and total replacement of the ankle: part 1: range of motion. *Foot Ankle Int.* 2003;24:881–7.
 15. Glazebrook MA, Arsenault K, Dunbar M. Evidence-based classification of complications in total ankle arthroplasty. *Foot Ankle Int.* 2009;30:945–9.
 16. Conti SF, Wong YS. Complications of total ankle replacement. *Clin Orthop Relat Res.* 2001;391:105–14.
 17. DiDomenico LA, Anania MC. Total ankle replacements: an overview. *Clin Podiatr Med Surg.* 2011;28:727–44.
 18. Jackson MP, Singh D. Total ankle replacement. *Curr Orthop.* 2003;17:292–8.
 19. Lechler P, Grifka J, Kock FX [Ankle arthroplasty: indications and current state]. *Orthopädie.* 2011;40:561–70.
 20. Steck JK, Anderson JB. Total ankle arthroplasty: indications and avoiding complications. *Clin Podiatr Med Surg.* 2009;26:303–24.
 21. Valderrabano V, Pagenstert G, Hintermann B. Total ankle replacement - three-component prosthesis. *Tech Foot and Ankle.* 2005;2: 84–90.
 22. DiDomenico LA, Treadwell JR, Cain LZ. Total ankle arthroplasty in the rheumatoid patient. *Clin Podiatr Med Surg.* 2010;27:295–311.
 23. Mayle Jr RE, DiGiovanni CW, Lin SS, et al. Current concepts review: venous thromboembolic disease in foot and ankle surgery. *Foot Ankle Int.* 2007;28:1207–16.
 24. Mizel MS, Temple HT, Michelson JD, et al. Thromboembolism after foot and ankle surgery. A multicenter study. *Clin Orthop Relat Res.* 1998;348:180–5.
 25. Solis G, Saxby T. Incidence of DVT following surgery of the foot and ankle. *Foot Ankle Int.* 2002;23:411–4.
 26. Conti SF, Wong YS. Complications of total ankle replacement. *Foot Ankle Clin.* 2002;7:791–807.
 27. Gadgil A, Thomas RH. Current trends in thromboprophylaxis in surgery of the foot and ankle. *Foot Ankle Int.* 2007;28:1069–73.
 28. Voleti PB, Donegan DJ, Kim TW, et al. Level of evidence: does it change the rate of publication and time to publication of American Academy of Orthopaedic Surgeons presentations? *J Bone Joint Surg Am.* 2013;95:e2.
 29. Bardelli M, Scoccianti G. Uncemented total ankle arthroplasty in post-traumatic osteoarthritis: 3- to 7-year follow-up. *J Orthop Traumatol.* 2006;7:93–6.
 30. Barg A, Knupp M, Hintermann B. Simultaneous bilateral vs unilateral total ankle replacement: a patient-based comparison of pain relief, quality of life and functional outcome. *J Bone Joint Surg Br.* 2010;92:1659–63.
 31. Barg A, Henninger HB, Knupp M, et al. Simultaneous bilateral total ankle replacement using a 3-component prosthesis: outcome in 26 patients followed for 2–10 years. *Acta Orthop.* 2011;82:704–10.
 32. • Barg A, Henninger HB, Hintermann B. Risk factors for symptomatic deep-vein thrombosis in patients after total ankle replacement who received routine chemical thromboprophylaxis. *J Bone Joint Surg Br.* 2011;93:921–7. *The only available clinical study specifically addressing the incidence of postoperative symptomatic deep-vein thrombosis and the risk factors of deep vein thrombosis in 665 patients with total ankle replacement. The incidence of symptomatic deep vein thrombosis was 3.9%. Following statistically significant independent risk factors have been identified: previous venous thromboembolic event, obesity, and postoperative non-weight-bearing.*
 33. Barg A, Knupp M, Anderson AE, et al. Total ankle replacement in obese patients: component stability, weight change, and functional outcome in 118 consecutive patients. *Foot Ankle Int.* 2011;32:925–32.
 34. Barg A, Knupp M, Henninger HB, et al. Total ankle replacement using HINTEGRA, an unconstrained, three-component system: surgical technique and pitfalls. *Foot Ankle Clin.* 2012;17:607–35.
 35. Barg A, Zwicky L, Knupp M, et al. HINTEGRA total ankle replacement: survivorship analysis in 684 patients. *J Bone Joint Surg Am.* 2013;95:1175–83.
 36. Besse JL, Brito N, Lienhart C. Clinical evaluation and radiographic assessment of bone lysis of the AES total ankle replacement. *Foot Ankle Int.* 2009;30:964–75.
 37. Bleazey ST, Brigido SA, Protzman NM. Perioperative complications of a modular stem fixed-bearing total ankle replacement with intramedullary guidance. *J Foot Ankle Surg.* 2013;52:36–41.
 38. Clement RC, Krynetskiy E, Parekh SG. The Total ankle arthroplasty learning curve with third-generation implants: a single surgeon's experience. *Foot Ankle Spec.* 2013;6:263–70.
 39. Dhawan R, Turner J, Sharma V, et al. Tri-component, mobile bearing, total ankle replacement-mid-term functional outcome and survival. *J Foot Ankle Surg.* 2012.
 40. Gallardo J, Lagos L, Bastias, et al. Continuous popliteal block for postoperative analgesia in total ankle arthroplasty. *Foot Ankle Int.* 2012;33:208–12.
 41. Haskell A, Mann RA. Perioperative complication rate of total ankle replacement is reduced by surgeon experience. *Foot Ankle Int.* 2004;25:283–9.
 42. Hintermann B. Die STAR-Sprunggelenkprothese: Kurz- und mittelfristige Erfahrungen. *Orthopädie.* 1999;28:792–803.
 43. Hintermann B, Valderrabano V. Endoprothetik am oberen Sprunggelenk. *Z ärztl Fortbild Qual sich (ZaeFQ).* 2001;95:187–94.
 44. Hintermann B, Valderrabano V, Knupp M, et al. Die HINTEGRA-Sprunggelenkprothese: Kurz- und mittelfristige Erfahrungen. *Orthopädie.* 2006;35:533–45.
 45. Hobson SA, Karantana A, Dhar S. Total ankle replacement in patients with significant pre-operative deformity of the hindfoot. *J Bone Joint Surg Br.* 2009;91:481–6.
 46. Karantana A, Hobson S, Dhar S. The Scandinavian total ankle replacement: survivorship at 5 and 8 years comparable to other series. *Clin Orthop Relat Res.* 2010;468:951–7.
 47. Karantana A, Martin GJ, Shandil M, et al. Simultaneous bilateral total ankle replacement using the S.T.A.R.: a case series. *Foot Ankle Int.* 2010;31:86–9.
 48. Knecht SI, Estin M, Callaghan JJ, et al. The Agility total ankle arthroplasty. Seven to 16-year follow-up. *J Bone Joint Surg Am.* 2004;86-A:1161–71.
 49. Kokkonen A, Ikavalko M, Tiihonen R, et al. High rate of osteolytic lesions in medium-term followup after the AES total ankle replacement. *Foot Ankle Int.* 2011;32:168–75.
 50. Kumar A, Dhar S. Total ankle replacement: early results during learning periods. *Foot Ankle Surg.* 2007;13:19–23.
 51. Lee KB, Cho SG, Hur CI, et al. Perioperative complications of HINTEGRA total ankle replacement: our initial 50 cases. *Foot Ankle Int.* 2008;29:978–84.
 52. Magnan B, Facci E, Bartolozzi P. Traumatic loss of the talus treated with a Talar body prosthesis and total ankle arthroplasty. A case report. *J Bone Joint Surg Am.* 2004;86:1778–82.
 53. Pagenstert G, Hintermann B. Simultaneous bilateral total knee and ankle arthroplasty as a single surgical procedure. *BMC Musculoskelet Disord.* 2011;12:233.

54. Rippstein PF, Huber M, Coetzee JC, et al. Total ankle replacement with use of a new three-component implant. *J Bone Joint Surg Am*. 2011;93:1426–35.
55. Rzesacz EH, Gossé F. Die Versorgung der posttraumatischen Arthrose des oberen Sprunggelenks durch die S.T.A.R.-Sprunggelenkprothese. *Oper Orthop Traumatol*. 2007;19:527–46.
56. Saltzman CL, Kadoko RG, Suh JS. Treatment of isolated ankle osteoarthritis with arthrodesis or the total ankle replacement: a comparison of early outcomes. *Clin Orthop Surg*. 2010;2:1–7.
57. Valderrabano V, Hintermann B. HINTEGRA-Sprunggelenkprothese: Präliminäre Resultate der ersten 125 Fälle. *Fuss Sprungg*. 2004;2:7–16.
58. van der Heide HJ, Schutte B, Louwerens JW, et al. Total ankle prostheses in rheumatoid arthropathy: outcome in 52 patients followed for 1–9 years. *Acta Orthop*. 2009;80:440–4.
59. Vienne P. Agility total ankle replacement. *Tech Foot and Ankle*. 2005;4:62–8.
60. Kofoed H. Cylindrical cemented ankle arthroplasty: a prospective series with long-term follow-up. *Foot Ankle Int*. 1995;16:474–9.
61. Patsalis T. Die AES-Sprunggelenksprothese: Indikation, Technik und erste Ergebnisse. *Fuss Sprungg*. 2004;2:38–44.
62. Alvine FG. The Agility ankle replacement: the good and the bad. *Foot Ankle Clin*. 2002;7:737–53.
63. Buechel Sr FF, Buechel Jr FF, Pappas MJ. Ten-year evaluation of cementless Buechel-Pappas meniscal bearing total ankle replacement. *Foot Ankle Int*. 2003;24:462–72.
64. Deorio JK. INBONE total ankle arthroplasty. *Semin Arthro*. 2010;21:288–94.
65. Rippstein PF. Clinical experiences with three different designs of ankle prostheses. *Foot Ankle Clin*. 2002;7:817–31.
66. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008;358:2776–86.
67. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358:2765–75.
68. Elsner A, Schiffer G, Jubel A, et al. The venous pump of the first metatarsophalangeal joint: clinical implications. *Foot Ankle Int*. 2007;28:902–9.
69. Oishi CS, Grady-Benson JC, Otis SM, et al. The clinical course of distal deep venous thrombosis after total hip and total knee arthroplasty, as determined with duplex ultrasonography. *J Bone Joint Surg Am*. 1994;76:1658–63.
70. Theodorou SJ, Theodorou DJ, Kakitsubata Y. Sonography and venography of the lower extremities for diagnosing deep vein thrombosis in symptomatic patients. *Clin Imaging*. 2003;27:180–3.
71. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. *J Bone Joint Surg Am*. 2005;87:2097–112.
72. Garino JP, Lotke PA, Kitziger KJ, et al. Deep venous thrombosis after total joint arthroplasty. The role of compression ultrasonography and the importance of the experience of the technician. *J Bone Joint Surg Am*. 1996;78:1359–65.
73. Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. *J Bone Joint Surg Br*. 1997;79:780–6.
74. White RH, Henderson MC. Risk factors for venous thromboembolism after total hip and knee replacement surgery. *Curr Opin Pulm Med*. 2002;8:365–71.
75. Hull RD, Raskob GE. Prophylaxis of venous thromboembolic disease following hip and knee surgery. *J Bone Joint Surg Am*. 1986;68:146–50.
76. Lotke PA, Steinberg ME, Ecker ML. Significance of deep venous thrombosis in the lower extremity after total joint arthroplasty. *Clin Orthop Relat Res*. 1994;299:25–30.
77. Kim YH. The incidence of deep vein thrombosis after cementless and cemented knee replacement. *J Bone Joint Surg Br*. 1990;72:779–83.
78. Healy B, Beasley R, Weatherall M. Venous thromboembolism following prolonged cast immobilization for injury to the tendo Achillis. *J Bone Joint Surg Br*. 2010;92:646–50.
79. Pearse EO, Caldwell BF, Lockwood RJ, et al. Early mobilization after conventional knee replacement may reduce the risk of postoperative venous thromboembolism. *J Bone Joint Surg Br*. 2007;89:316–22.
80. Prandoni P. How I, treat venous thromboembolism in patients with cancer. *Blood*. 2005;106:4027–33.
81. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA*. 2005;293:715–22.
82. Jameson SS, Augustine A, James P, et al. Venous thromboembolic events following foot and ankle surgery in the English National Health Service. *J Bone Joint Surg Br*. 2011;93:490–7.